PMID- 35212019 OWN - NLM STAT- MEDLINE DCOM- 20220809 LR - 20220809 IS - 1099-1069 (Electronic) IS - 0278-0232 (Linking) VI - 40 IP - 3 DP - 2022 Aug TI - Prognostic factors of children and adolescents with T-cell acute lymphoblastic leukemia after allogeneic transplantation. PG - 457-468 LID - 10.1002/hon.2980 [doi] AB - Acute lymphoblastic leukemia (ALL) is the most common cancer during childhood, and some high-risk patients with ALL require hematopoietic stem cell transplantation (HSCT). Mainly due to small patient numbers, studies focusing specifically on children and adolescents with T-cell ALL (T-ALL) are limited. Using a nationwide registry, we retrospectively analyzed data from patients under 20 years old who underwent their first HSCT for T-ALL between 2000 and 2018. As a result, total 484 patients were included, and their median follow-up period was 6.9 years after HSCT for survivors. While patients receiving HSCT at first complete remission (CR) showed relatively good 5-year leukemia free survival (5yLFS, 73.5%), once relapse occurred, their prognosis was much worse (44.4%) even if they attained second remission again (p < 0.001). Among patients receiving HSCT at CR1, grade II-IV acute graft versus host disease was associated with worse overall and LFS than grade 0-I (5yLFS 69.5% vs. 82.1%, p = 0.026) mainly due to high non-relapse mortality. Among those patients, patients receiving related bone marrow transplantation, unrelated bone marrow transplantation, or unrelated cord blood transplantation showed similar survival (5yLFS, 73.2%, 76.3%, and 77.0%, respectively). For patients undergoing cord blood transplantation at CR1, total-body irradiation-based myeloablative conditioning was associated with better 5yLFS than other conditioning regimens (85.4% vs. 62.2%, p = 0.044), as it reduced the risk of relapse. These results indicate that relapsed patients have much less chance of cure, and that identifying patients who require HSCT for cure and offering them HSCT with optimal settings during CR1 are crucial for children and adolescents with T-ALL. CI - (c) 2022 John Wiley & Sons Ltd. FAU - Ishida, Hisashi AU - Ishida H AUID- ORCID: 0000-0002-3391-8403 AD - Department of Pediatrics, Okayama University Hospital, Okayama, Japan. FAU - Kato, Motohiro AU - Kato M AD - Department of Pediatrics, The University of Tokyo Hospital, Tokyo, Japan. FAU - Kawahara, Yuta AU - Kawahara Y AUID- ORCID: 0000-0002-0192-7233 AD - Department of Pediatrics, Jichi Medical University School of Medicine, Shimotsuke, Japan. FAU - Ishimaru, Sae AU - Ishimaru S AD - Department of Pediatric Oncology, National Cancer Center Hospital, Tokyo, Japan. FAU - Najima, Yuho AU - Najima Y AD - Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan. FAU - Kako, Shinichi AU - Kako S AUID- ORCID: 0000-0002-2635-3395 AD - Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan. FAU - Sato, Maho AU - Sato M AD - Department of Hematology/Oncology, Osaka Women's and Children's Hospital, Izumi, Japan. FAU - Hiwatari, Mitsuteru AU - Hiwatari M AUID- ORCID: 0000-0003-3683-4472 AD - Department of Pediatrics, The University of Tokyo Hospital, Tokyo, Japan. FAU - Noguchi, Maiko AU - Noguchi M AD - Department of Pediatrics, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan. FAU - Kato, Keisuke AU - Kato K AD - Division of Pediatric Hematology and Oncology, Ibaraki Children's Hospital, Ibaraki, Japan. FAU - Koh, Katsuyoshi AU - Koh K AD - Department of Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan. FAU - Okada, Keiko AU - Okada K AD - Department of Pediatric Hematology/Oncology, Osaka City General Hospital, Osaka, Japan. FAU - Iwasaki, Fuminori AU - Iwasaki F AD - Division of Hematology/Oncology, Kanagawa Children's Medical Center, Yokohama, Japan. FAU - Kobayashi, Ryoji AU - Kobayashi R AD - Department of Hematology/Oncology for Children and Adolescents, Sapporo Hokuyu Hospital, Sapporo, Japan. FAU - Igarashi, Shunji AU - Igarashi S AD - Department of Pediatric Hematology/Oncology, Japanese Red Cross Narita Hospital, Narita, Japan. FAU - Saito, Shoji AU - Saito S AD - Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan. FAU - Takahashi, Yoshiyuki AU - Takahashi Y AD - Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan. FAU - Sato, Atsushi AU - Sato A AD - Department of Hematology and Oncology, Miyagi Children's Hospital, Sendai, Japan. FAU - Tanaka, Junji AU - Tanaka J AUID- ORCID: 0000-0002-7026-1455 AD - Department of Hematology, Tokyo Women's Medical University, Tokyo, Japan. FAU - Hashii, Yoshiko AU - Hashii Y AD - Department of Cancer Immunotherapy/Pediatrics, Osaka University Graduate School of Medicine, Osaka, Japan. FAU - Atsuta, Yoshiko AU - Atsuta Y AD - Japanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Japan. AD - Department of Registry Science for Transplant and Cellular Therapy, Aichi Medical University School of Medicine, Nagakute, Japan. FAU - Sakaguchi, Hirotoshi AU - Sakaguchi H AD - Children's Cancer Center, National Center for Child Health and Development, Tokyo, Japan. FAU - Imamura, Toshihiko AU - Imamura T AD - Department of Pediatrics, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan. LA - eng PT - Journal Article DEP - 20220303 PL - England TA - Hematol Oncol JT - Hematological oncology JID - 8307268 SB - IM MH - Adolescent MH - Adult MH - Child MH - *Graft vs Host Disease/complications MH - *Hematopoietic Stem Cell Transplantation/methods MH - Humans MH - *Precursor Cell Lymphoblastic Leukemia-Lymphoma/etiology/therapy MH - *Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/therapy MH - Prognosis MH - Recurrence MH - Retrospective Studies MH - T-Lymphocytes MH - Transplantation Conditioning/methods MH - Transplantation, Homologous MH - Young Adult OTO - NOTNLM OT - adolescent OT - child OT - graft versus host disease OT - lymphoid leukemia OT - stem cell transplantation EDAT- 2022/02/26 06:00 MHDA- 2022/08/10 06:00 CRDT- 2022/02/25 05:42 PHST- 2022/01/24 00:00 [revised] PHST- 2021/12/12 00:00 [received] PHST- 2022/02/18 00:00 [accepted] PHST- 2022/02/26 06:00 [pubmed] PHST- 2022/08/10 06:00 [medline] PHST- 2022/02/25 05:42 [entrez] AID - 10.1002/hon.2980 [doi] PST - ppublish SO - Hematol Oncol. 2022 Aug;40(3):457-468. doi: 10.1002/hon.2980. Epub 2022 Mar 3.